Inflammatory bowel disease: Immunologic concepts

Hepato-Gastroenterology

Volumn 47, Issue 31, 2000, Pages 15-28

  Schreiber, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INFLIXIMAB;

ANTIGEN PRESENTATION; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIGEN PRESENTATION; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0033952758     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. 1 Poletti PA, Halton A, Marti MC: Papilloma virus and anal carcinoma. Int J Colorectal Dis 1998; 13:108-111.
2. 2 Green SE, Bradburn DM, Varma JS, Burn J: Hereditary non-polyposis colorectal cancer. Int J Colorectal Dis 1998; 13:3-12.
3. 3 Saverymuttu SH, Peters AM, Lavender JP, Pepys MB, Hodgson HJ, Chadwick VS: Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease activity in Crohn's disease. Gastroenterology 1983; 85:1333-1339.
4. 4 Saverymuttu SH, Peters AM, Lavender JP, Chadwick VS, Lavender JP: In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease. Gut 1985; 26:378-383.
5. 5 Schölmerich J, Schmidt E, Schumichen C, Billmann P, Schmidt H, Gerok W: Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m hexamethyl propylene amine oxine as leukocyte label. Gastroenterology 1988; 95:1287-1293.
6. 6 Grisham MB, Granger DN: Neutrophil mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 1988; 33:6S-15S.
7. 7 Faden H, Rossi TM: Chemiluminescent response of neutrophils from patients with inflammatory bowel disease. Dig Dis Sci 1985; 30:139-142.
8. 8 Anton PA, Targan SR, Shanahan F: Increased neutrophil receptors for and response to the pro-inflammatory bacterial peptide formyl-methionyl-leucylphenylalanine in Crohn's disease. Gastroenterology 1989; 97:20-28.
9. 9 Kelleher D, Feighery C, Weir DG: Chemiluminescence by polymorphonuclear leukocyte subpopulations in chronic inflammatory bowel disease. Influence of the cell separation procedure. Digestion 1990; 45:158-165.
10. 10 Baldassano RN, Schreiber S, Johnston RB, Muraki T, MacDermott RP: Monocytes of patients with Crohn's disease are primed for accentuated release of toxic oxygen metabolites: possible role for endotoxin. Gastroenterology 1993; 105:60-66.
11. 11 Griga T, Tromm A, Schwegler U, May B: Enhanced superoxide anion release of normal neutrophil granulocytes primed with sera of patients with inactive inflammatory bowel disease. Z Gastroentrol 1995; 33:345-348.
12. 12 Andus T, Gross V, Caesar I, Krumm D, Hosp J, Gerok W, Schölmerich J: PMN-elastase in assessment of patients with inflammatory bowel disease. Dig Dis Sci 1993; 38: 1638-1644.
13. 13 Adeyemi EO, Hodgson HJ: Fecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol 1992; 27:139-142.
14. 14 Duchmann R, Kaiser I, Herrmann E, Mayet W, Ewe K, Meier zum Büschenfelde KH: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:448-455.
15. 15 Schurmann G, Bruwer M, Klotz A, Schmid KW, Seninger N, Zimmer KP: Transepithelial transport processes at the intestinal mucosa in inflammatory bowel disease. Int J Colorectal Dis 1999; 14:41-46.
16. 16 Mahida YR, Wu K, Jewell DP: Enhanced production of interleukin 1-β by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's disease. Gut 1989; 30:835-838.
17. 17 Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D: Role of interleukin 1 in inflammatory bowel disease -enhanced production during active disease. Gut 1990; 31:686-689.
18. 18 Brynskov J, Tvede N, Andersen CB, Vilien M: Increased concentrations of interleukin 1β, interleukin 2, and soluble interleukin-2 receptors in endoscopic mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992; 33:55-58.
19. 19 Pullman WE, Elsbury S, Masanobu K, Hapel AJ, Doe WF: Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992; 102:529-537.
20. 20 Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S: Increased secretion of pro-inflammatory cytokines by polymorphonuclear neutrophils and regulation by Interleukin 10 in inflammatory bowel disease. Gut 1998; 42:470-476.
21. 21 Reinecker H-C, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A: Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94:174-181.
22. 22 Schreiher S, Nikolaus S, Hampe J, Hamling J, Groessner B, Lochs A, Raedle A: Tumour necrosis factor alpha and interleukin-1 beta in relapse of Crohn's disease. Lancet 1999; 353:459-461.
23. 23 Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, Antonioli D, Peppercorn MA, Strom TB: Tumor necrosis factor-a, interleukin-1β and interleukin 6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37:818-826.
24. 24 Isaacs KL, Sartor RB, Haskill S: Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992; 103:1587-1595.
25. 25 Woywodt A, Neustock P, Kruse A, Schwarting K, Ludwig D, Stange EF, Kirchner H: Cytokine expression in intestinal mucosal biopsies. In situ hybridisation of the mRNA for interleukin-1 beta, interleukin-6 and tumour necrosis factor-alpha in inflammatory bowel disease. Eur-Cytokine-Newt 1994; 5:387-395.
26. 26 Rogler G, Andus T, Aschenbrenner E, Vogl D, Falk W, Scholmerich J, Gross V: Alterations of the phenotype of colonic macrophages in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9:893-899.
27. 27 Kern JA, Lamb RJ, Reed JC, et al: Dexamethasone inhibition of interleukin-1-beta production by human monocytes. J Clin Invest 1988; 81:237-244.
28. 28 Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
29. 29 van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric antibody (cA2). Gastroenterology 1995; 109:129-135.
30. 30 Baert FJ, Rutgeerts PR: Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorectal Dis 1999; 14(1):47-51.
31. 31 Lieberman BY, Fiocchi C, Youngman KR, Sapatnekar WK, Proffitt MR: Interferon gamma production by human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel disease. Dig Dis Sci 1988; 33:1297-1304.
32. 32 Stallmach A, Schafer F, Hoffman S, Weber S, Muller-Molaian I, Schneider T, Kohne G, Ecker KW, Feifel G, Zeitz M: Increased state of activation of CD4 positive T cells and elevated interferon gamma production in pouchitis. Gut 1998; 43:499-505.
33. 33 Stallmach A, van Look M, Scheiffele F, Ecker KW, Feifel G, Duchmann R, Zeitz M: IgG, albumin, and sCD44 in whole-gut lavage fluid are useful clinical markers for assessing the presence and activity of pouchitis. Int J Colorectal Dis 1999; 14:35-40.
34. 34 Hampe J, Hermann B, Bridger S, MacPherson AJ, Mathews CG, Schreiber S: The interferon-gamma gene as a positive and functional candidate gene for inflammatory bowel disease. Int J Colorectal Dis 1998; 13(5-6):260-263.
35. 35 Essner R, Rhoades K, McBride WH, Morton DL, Esconomou JS: IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989; 142:3857-3861.
36. 36 Donnelly RP, Fenton MJ, Finbloom DS, Gerrard TL: Differential regulation of IL-1 production in human monocytes by IFN-g and IL-4. J Immunol 1990; 145:569-575.
37. 37 Vannier E, Miller LC, Dinarello CA: Coordinated antiinflammatory effects of interleukin 4: Interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992; 89:4076-4080.
38. 38 Karttunnen R, Breese EJ, Walker-Smith JA, MacDonald TT: Decreased mucosal interleukin-4 production in gut inflammation. J Clin Pathol 1994; 47:1015-1018.
39. 39 West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C: Interleukin 4 in inflammatory bowel and mucosal immune reactivity. Gastroenterology 1996; 110:1683-1695.
40. 40 Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, Ectors N, Cortot A, Capron M, Colombel JF: Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997; 113:118-126.
41. 41 Mosmann TR: Regulation of immune responses by T cells with different cytokine secretion profiles: Role of a new cytokine, cytokine synthesis inhibitory factor (IL-10). Int Arch Allergy Appl Immunol 1991; 94:110-115.
42. 42 de Waal Malefyt R, Yssel H, Roncarolo M-G, Spits H, de Vries JE: Interleukin 10. Curr Opin Immunol 1992; 4:314-322.
43. 43 Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147:3815-3822.
44. 44 Ralph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, Min H-Y, Lin L: IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992; 148:808-814.
45. 45 Oswald IP, Gazzinelli RT, Sher A, James SL: IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J Immunol 1992; 148:3578-3582.
46. 46 Fiorentino DF, Zlotnik A, Viera P, Mosmann TR, Howard M, Moore KW, O'Garra A: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-3451.
47. 47 de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-1220.
48. 48 Fiorentino DF, Bond MW, Mosmann TR: Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081-2085.
49. 49 Schreiber S, Heinig T, Thiele HG, Raedler A: Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108:1434-1444.
50. 50 Schottelius AJG, Mayo MW, Sartor RB, Baldwin AS: Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J Biol Chem 1999; 274:31868-31874.
51. 51 Seitz M, Loetscher P, Dewald B, Towbin H, Ceska M, Baggiolini M: Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and prostaglandin E by rheumatoid and osteoarthritic synoviocytes-regulation by IFN-gamma and IL-4. J Immunol 1994; 152:2060-2065.
52. 52 Wirth JJ, Kierszenbaum F, Zlotnik A: Effects of IL-4 on macrophage functions: increased uptake and killing of a protozoan parasite (Trypanosoma cruzi). Immunology 1989; 66:296-301.
53. 53 Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffmann RL: Inhibition of TH1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45RB (high) CD4 T cells. Immunity 1994; 1:553-562.
54. 54 Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Stahl PD, et al: Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995; 108:21-33.
55. 55 Kucharzik T, Lügering N, Weigelt H, Adolf M, Domschke W, Stoll R: Comparison of the suppressive effects of interleukin-13, interleukin-10, and interleukin-4 on blood monocytes from patients with IBD. Gastroenterology, 1996; 110:A943. (Abstract)
56. 56 Fukushima K, West GA, Klein JS, Levine AD, Fiocchi C: Opposite modulatory activity of IL-10 and IL-4 on lamina propria mononuclear cells (LpMC) is stimulus-dependent. Gastroenterology 1993; 104:A702. (Abstract)
57. 57 Matsuura T, West GA, Klein JS, Levine AD, Kusugami K, Morise K, Fiocchi C: Immune activation gene products are resistent to IL-4 inhibitory activity in Crohn's disease (CD). Gastroenterology 1993; 104:A739. (Abstract)
58. 58 Lenardo MJ, Baltimore D: NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58:227-229.
59. 59 Baldwin AS: The NF-KB and I-KB proteins: New discoveries and insights. Ann Rev Immunol 1996; 14:649-681.
60. 60 Schottelius AJG, Baldwin AS: A role for transcription factor NF-κB in intestinal inflammation. Int J Colorectal Dis 1999; 14:18-28.
61. 61 Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U: Control of IkB-a proteolysis by site-specific signal induced phosphorylation. Science 1995; 267:1485-1487.
62. 62 Neurath MF, Petterson S, Meger zum Büschenfelde KH, Strober W: Local administration of antisense phosphothiocate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nature Medicine 1996; 2:998-1004.
63. 63 Schreiber S, Nikolaus S, Hampe J: Activation of Nuclear Factor kappa B in Inflammatory Bowel Disease. Gut 1998, 42:477-485.
64. 64 Strickland RG, Korsmeyer S, Soltis RD, et al: Peripheral blood T and B cells in chronic inflammatory bowel disease. Gastroenterology 1974; 67:569-577.
65. 65 Thayer WR, Charland C, Field CE: The subpopulations of circulating white blood cells in inflammatory bowel disease. Gastroenterology 1976; 71:379-384.
66. 66 Auer IO, Wechsler W, Ziemer E, et al: Immune status in Crohn's disease, I. Leukocyte and lymphocyte subpopulations in peripheral blood. Scan J Gastroenterol 1978; 13:561-571.
67. 67 Auer IO, Gotz S, Ziemer E, et al: Immune status in Crohn's disease, 3. Peripheral blood lymphocytes, enumerated by means of F(ab)2-antibody fragments, null and T lymphocytes. Gut 1979; 20:261-268.
68. 68 Selby WS, Jewell DP: T lymphocyte subsets in inflammatory bowel disease: peripheral blood. Gut 1983; 24:99-105.
69. 69 Yuan SZ, Hanauer SB, Kluskens LF, et al: Circulating lymphocyte subpopulations in Crohn's disease. Gastroenterology 1983; 85:1313-1318.
70. 70 Raedler A, Fraenkel S, Klose G, et al: Involvement of the immune system in the pathogenesis of Crohn's disease. Expression of the T9 antigen on peripheral immunocytes correlated with the severity of the disease. Gastroenterology 1985; 88:978-983.
71. 71 Raedler A, Fraenkel S, Klose G, et al: Elevated numbers of peripheral T cells in inflammatory bowel diseases displaying T9 antigen and Fc alpha receptors. Clin Exp Immunol 1985; 60:518-524.
72. 72 Schreiber S, Nash GS, Raedler A, et al: Human lamina propria mononuclear cells are activated in inflammatory bowel disease. In: Tsuchiya M, Nagura H, Hibi T, Moro I, (Eds.). Frontiers of mucosal immunology. Amsterdam: Elsevier, 1991; pp. 749-753.
73. 73 Raedler A, Schreiber S, Schulz KH, et al: Activated Fc-alpha T-cells in Crohn's disease are involved in regulation of IgA. Adv Exp Med Biol 1988; 237:665-673.
74. 74 Raedler A, Bredow G, Kirch W, et al: In vivo activated T cells in autoimmune disease. J Clin Lab Immunol 1986; 19:181-186.
75. 75 Pallone F, Fais S, Squarcia O, et al: Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 1987; 28:745-753.
76. 76 Fais S, Pallone F, Squarcia O, Boirivant M, Pozzilli P: T cell early activation antigens expressed by peripheral lymphocytes in Crohn's disease. J Clin Lab Immunol 1985; 16:75-76.
77. 77 Kontinen YT, Bergroth V, Nordström D, Segerberg-Konttinen M, Seppälä K, Salaspuro M: Lymphocyte activation in vivo in the intestinal mucosa of patients with Crohn's disease. J Clin Lab Immunol 1987; 22:59-63.
78. 78 Fais S, Pallone F, Sqarcia O, Biancone L, Ricci F, Paoluzzi P, Boivirant M: HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin Exp Immunol 1987; 68:605-612.
79. 79 MacDonald TT, Choy MY, Hutchings P, Cooke A: Activated T cells and macrophages in the intestinal mucosa of children with inflammatory bowel disease. In: MacDonald TT, Chalacombe SJ, Bland PW, Stokes CR, Heatley RC, Movat AM (Eds.). Advances in mucosal immunology. Boston: Kluwer, 1990; pp. 683-690.
80. 80 Allison CM, Poulter LW, Dhillon AP, Pounder RE: Immunohistochemical studies of surface antigen on colonic lymphoid cells in normal and inflamed mucosa. Gastroenterology 1990; 99:421-430.
81. 81 Selby WS, Janossy G, Bofill M, Jewell DP: Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistochemical and cell isolation techniques. Gut 1984; 25:32-40.
82. 82 Fais S, Pallone F: Ability of human colonic epithelium to express the 4F2 Antigen, the common acute lymphoblastic leukemia antigen and the transferrin receptor. Gastroenterology 1989; 97:1435-1441.
83. 83 Schreiber S, Raedler A, Stenson WF, MacDermott RP: The immunology of inflammatory bowel disease. Gastroenterol Clin North Am 1992; 21:451-502
84. 84 Trejdosiewicz LK, Badr-el-Din S, Smart CJ, Malizia G, Oakes DJ, Heatley RV, Losowsky MS: Colonic mucosal T Lymphocytes in ulcerative colitis: expression of CD7 antigen in relation to MHC class II (HLA-D) antigens. Dig Dis Sci 1989; 34(9): 1449-1456.
85. 85 Brynskov J, Tvede N: Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin. Gut 1990; 31:795-799.
86. 86 Müller C, Knoflach P, Zielinski CC: T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells. Gastroenterology 1990; 98:639-646.
87. 87 Proujansky R, Carpenter AB: Soluble interleukin-2 receptor as a marker of lymphocyte activation in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1991; 13:277-284.
88. 88 Nielsen OH, Ciardelli T, Wu Z, Langholz E, Kirman I: Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease. Am J Gastroenterol 1995; 90:1301-1306.
89. 89 Schurmann G, Betzler M, Post S, Herfarth C, Meuer S: Soluble interleukin-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: preoperative levels and postoperative changes of serum concentrations. Digestion 1992; 51:51-59.
90. 90 Dalekos GN, Manoussakis MN, Goussia AC, Tsianos EV, Moutsopoulos HM: Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis. Gut 1993; 34:658-664.
91. 91 Crabtree JE, Juby LD, Heatley RV, Lobo AJ, Bullimore DW, Axon AT: Soluble interleutkin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity. Gut 1990; 31:1033-1036.
92. 92 Louis E, Belaiche J, Van-Kemseke C, Schaaf N, Mahieu P, Mary JY: Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and predicition of relapse. Dig Dis Sci 1995; 40:1750-1756.
93. 93 Williams AJ, Symons JA, Watchet K, Duff GW: Soluble interleukin-2 receptor and disease activity in Crohn's disease. J Autoimmun 1992; 5:251-259.
94. 94 Mahida YR, Gallagher A, Kurlak L, Hawkey CJ: Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease. Clin Exp Immunol 1990; 82:75-80.
95. 95 Schreiber S, Raedler A, Conn AF, Rombeau JL, MacDermott RP: Increased release of soluble interleukin-2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease. Gut 1992; 32: 236-241.
96. 96 Schreiber S, MacDermott RP, Raedler A, Pinnau R, Bertovich M, Nash GS: Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991; 101:1020-1030.
97. 97 MacDermott RP, Schloemann SR, Bertovich MJ, et al: Inhibition of antibody synthesis by 5-aminosalicylic acid. Gastroenterology 1989; 96:442-448.
98. 98 Kaulfersch W, Fiocchi C, Waldmann TH: Polyclonal nature of the intestinal mucosal lymphocyte populations in inflammatory bowel disease. Gastroenterology 1988; 95:364-370.
99. 99 Blumberg RS, Yockey CE, Gross GG, Ebert EC, Balk SP: Human intestinal intraepithelial lymphocytes are derived from a limited number of T cells clones that utilize multiple V beta T cell receptor genes. J Immunol 1993; 1:5144-5153.
100. 100 Robijn RJ, Bloemendal H, Jainandunsing S, Wiegman LJ, Van Berge-Henegouwen GP, Logtenberg T, Koningsberger JC: Phenotypic and molecular characterization of human monoclonal TCR gamma/delta T cell lines from jejunum and colon of healthy individuals. Scand J Immunol 1993; 38:247-253.
101. 101 Pluschke G, Taube H, Krawinkel U, Pfeffer K, Wagner H, Glassen M, Deusch K: Oligoclonality and skewed T cell receptor V beta gene segment expression in in vivo activated human intestinal intraepithelial T lymphocytes. Immunobiology 1994; 192:77-93.
102. 102 Yacyshyn BR: Activated CA19+ B cell lamina propria lymphocytes in ulcerative colitis. Immunol Cell Biol 1993; 71:265-274.
103. 103 Yacyshyn BR, Meddings JB: CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology 1995; 108:132-137.
104. 104 Halstensen TS: Anders Jahre Prize for young researches 1994. Chronic intestinal inflammation studies with multicolored immunohistochemistry. Nord Med 1995; 110:56-59.
105. 105 Brandtzaeg P, Bosnes V, Halstensen TS, Scott H, Sollid LM, Valnes KN: T lymphocytes in human gut epithelium preferentially express the alpha/beta antigen receptor and are often CD45/UCHL1 -positive. Scand J Immunol 1989; 30:123-128.
106. 106 Caballero T, Nogueras F, Medina MT, Caracuel MD, de Sola C, Martinez-Salmeron FJ, Rodrigo M, Garciadel Moral R: Intraepithelial and lamina propria leukocyte subsets in inflammatory bowel disease: an immunohistochemical study of colon and rectal biopsy specimens. J Clin Pathol 1995; 48:743-748.
107. 107 Powrie F: T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995; 3:171-174.
108. 108 Peters MG, Secrist H, Anders KA, Nash GS, Rich SR, MacDermott RP: Normal human intestinal B lymphocytes: Increased activation compared to peripheral blood. J Clin Invest 1989; 83:1827-1833.
109. 109 Zeitz M, Greene WC, Pfeffer NJ, James SP: Lymphocytes isolated from the intestinal lamina propria of normal nonhuman primates have increased expression of genes associated with T cell activation. Gastroenterology 1988; 94:647-655.
110. 110 MacDermott RP, Nash GS, Bertovich MJ, et al: Alterations of IgA IgM, and IgG by peripheral blood mononuclear cells, and by human bone marrow mononuclear cells from patients with ulcerative colitis and Crohn's disease. Gastroenterology 1981; 81:844-852.
111. 111 MacDermott RP, Delacroix DL, Nash GS, et al: Evidence for the migration of B cells secreting monomeric IgA and IgA subclass 1 (IgA1) from peripheral compartments into the intestine in inflammatory bowel disease. Gastroenterology 1986; 91:379-385.
112. 112 James SP, Murakawa Y, Kanof ME, et al: Role of intestinal T-cells and intestinal lymphokine production in inflammatory bowel disease. In: Tsuchiya M, Nagura H, Hibi T, Moro I (Eds.). Frontiers of mucosal immunology. Amsterdam: Elsevier, 1991; pp. 727-731.
113. 113 Kansas GS, Wood GS, Fishwild DM, et al: Functional characterization of human T-lymphocyte subsets distinguished by monoclonal anti-leu-8. J Immunol 1985; 134:2995-3000.
114. 114 James SP, Fiocchi C, Graeff AS, et al: Phenotypic analysis of lamina propria lymphocytes: predominance of helper-inducer and cytolytic T-cell phenotypes and deficiency of supressor-inducer phenotypes in Crohn's disease and control patients. Gastroenterology 1986; 91:1483-1492.
115. 115 Kanof ME, Strober W, Fiocchi C, et al: CD4 positive leu-8 negative helper-inducer T cells predominate in the human intesinal lamina propria. J Immunol 1988, 141:3036-3041.
116. 116 Scott MG, Nahm MH, Macke K, et al: Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease and controls. Clin Exp Immunol 1986; 66:209-215.
117. 117 MacDermott RP, Nahm MH: Expression of human immunoglobulin G subclassed in inflammatory bowel disease. Gastroenterology 1987; 93:1127.
118. 118 Neurath MF, Fuss I, Kelsall BL, Stuber E, Stober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182:1281-1290.
119. 119 Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Büschenfelde KH, Strober W, Kollias G: Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997; 27:1743-1750.
120. 120 Gross V, Andus T, Leser HG, Roth M, Schölmerich J: Inflammatory mediators in chronic inflammatory bowel disease. Klein Wochenschr 1991; 69:981-987.
121. 121 Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP: Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992; 102:1620-1627.
122. 122 Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157:1261-1270.
123. 123 Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, Pallone F: Interleukin 12 is expressed and actively released by Crohn's disease lamina propria mononuclear cells. Gastroenterology 1997; 112:1169-1178.
124. 124 Bauditz J, Ortner M, Bierbaum M, Niedobitek M, Lochs H, Schreiber S: Human host defence against helicobacter pylori: role of pro-inflammatory cytokines IL-12, TNF-α, IL-1β, IL-6 and IL-8. Gastroenterology 1997; 112:A67.
125. 125 Diment S, Stahl P: Macrophage endosomes contain proteases which degrade endocytosed protein ligands. J Biol Chem 1985; 260:15311-15315.
126. 126 Unanue ER, Allen PM: The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987; 236:551-554.
127. 127 Allen PM, Unanue ER: Differential requirement for antigen processing by macrophages for lysozyme-specific T-cell hybridomas. J Immunol 1984; 132:1077-1082.
128. 128 Adorini LS, Muller S, Cardinaux F, Lehmann PV, Falcioni F, Nagy ZA: In vivo competition between self peptides and foreign antigens in T cell activation. Nature 1988; 334:623-625.
129. 129 Lorenz RG, Blum JS, Allen PM: Constitutive competition by self proteins for antigen presentation can be overcome by receptor-enhanced uptake. J Immunol 1990; 144:1600-1606.
130. 130 Schreiber S, Stenson WF, MacDermott RP, Chappel JC, Teitelbaum SL, Perkins SL: Aggregated bovine IgG inhibits mannose receptor expression of murine bone marrow derived macrophages via activation. J Immunol 1991; 147:1377-1382.
131. 131 Marodi L, Schreiber S, Anderson DC, MacDermott RP, Korchak HM, Johnston RB: Enhancement of macrophage candidacidal activity by interferon-γ: increased phagocytosis killing and calcium signal mediated by a decreased number of mannose receptors. J Clin Invest, 1993; 91:2596-2601.
132. 132 Schreiber S, Blum JC, Chappel JC, Stenson WF, Stahl PD, Teitelbaum SL, Perkins SL: PGE specifically upregulates the expression of the mannose-receptor on mouse bone marrow derived macrophages. Cell Regulation 1990; 1:403-413.
133. 133 Schreiber S, Blum JC, Stenson WF, MacDermott RP, Stahl PD, Teitelbaum SL, Perkins SL: Monomeric IgG2a promotes maturation of bone marrow macrophages and expression of the mannose receptor. Proc Natl Acad Sci USA 1991; 88:1616-1620.
134. 134 Rugveit J, Haraldsen G, Hogasen AK, Bakka A, Brandtzaeg P, Scott H: Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14(+)L14(+) monocyte derived cells. Gut 1995; 37:367-373.
135. 135 Karp DR, Teletski CL, Scholl P, Geha R, Long EO: The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin 1. Nature 1990; 346:474-476.
136. 136 Aisenberg J, Ebert EC, Mayer L: T-cell activation in human intestinal mucosa: the role of superantigens. Gastroenterology 1993; 105:1421-30.
137. 137 Shalon L, Gulwani-Akolkar B, Fisher SE, Akolkar PN, Panja A, Mayer L, Silver J: Evidence for an altered T-cell receptor repertoire in Crohn's disease. Autoimmunity 1994; 17:301-307.
138. 138 Baca-Estrada ME, Wong DK, Croitoru K: Cytotoxic activity of V beta 8+ T cells in Crohn's disease: the role of bacterial superantigens. Clin Exp Immunol 1995; 99:398-403.
139. 139 Holtmeier W, Chowers Y, Lumeng A, Morzycka-Woblenska E, Kagnoff MF: The delta T cell receptor repertoire in human colon and peripheral blood in oligoclonal irrespective of V region usage. J Clin Invest 1995; 96:1108-1117.
140. 140 Duchmann R, Kaiser I, Herrmann E, Mayet W, Ewe K, Meier zum Büschenfelde KH: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:448-455.
141. 141 Fais S, Pallone F, Squarcia O, Biancone L, Ricci F, Paoluzi P, Boirivant M: HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin Exp Immunol 1987; 68:605-612.
142. 142 Hirata I, Austin LL, Bleckwell WH, Weber JR, Dobbins WO: Immunoelectron microscopic localization of HLA-DR antigen in control small intestine and colon and in inflammatory bowel disease. Dig Dis Sci 1986; 31:1317-3130.
143. 143 McDonald GB, Jewell DP: Glass II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon. J Clin Pathol 1987; 40:312-317.
144. 144 Selby WS, Janossy G, Mason DY, Jewell DP: Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol 1983; 53:614-618.
145. 145 Iizuka M, Chiba M, Ohta H, Kodama K, Igarashi K, Arakawa H, Masamune O: Expression of HLA-DR antigens on colonic epithelium in ulcerative colitis. Gastroenterol Jpn 1987; 22:571-577.
146. 146 Bland P: MHC class II expression by the gut epithelium. Immunol Today 1988; 9:174-178.
147. 147 Mayer L, Shlien R: Evidence for function of Ia molecules on gut epithelial cells in man. J Exp Med 1987; 166:1471-1483.
148. 148 Mayer L, Eisenhardt D, Salomon P, Bauer W, Plous R, Piccinini L: Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease. Gastroenterology 1991; 100:3-12.
149. 149 Rognum TO, Brandtzaeg P, Elgjo K, Fausa O: Heterogeneous epithelial expression of class II(HLA-DR) determinants and secretory component related to dysplasia in ulcerative colitis. Br J Cancer 1987; 56:419-424.
150. 150 Panja A, Barone A, Mayer L: Stimulation of lamina propria lymphocytes by intestinal epithelial cells: evidence for recognition of non-classical restriction elements. J Exp Med 1994; 179:943-950.
151. 151 Panja A, Blumberg RS, Balk SP, Mayer L: CD1d is involved in T cell-intestinal epithelial cell interactions. J Exp Med 1993; 178:1115-1119.
152. 152 Blumberg RS, Balk SP: Intraepithelial lymphocytes and their recognition of non-classical MHC molcules. Int Rev Immunol 1994; 11:15-30.
153. 153 Balk SP, Burke S, Polischuk JE, Frantz ME, Yang L, Porcelli S, Colgan SP, Blumberg RS: Beta 2-microglobulin-independent MCH class Ib molecule expressed by human intestinal epithelium. Science 1994; 265:259-262.
154. 154 Balk SP, Ebert EC, Blumenthal RL, McDermott FV, Wucherpfennig KW, Landau SB, Blumberg RS: Oligoclonal expansion and CD1 recognition by human intestinal intraepithelial lymphocytes. Science 1991; 253:1411-1415.
155. 155 Rosenberg WM, Prince C, Kaklamanis L, Fox SB, Jackson DG, Simmons DL, Chapman RW, Trowell JM, Jewell DP, Bell JI: Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. Lancet 1995; 345:1205-1209.
156. 156 Watanabe T, Kubota Y, Muto T: Substance P containing nerve fibers in ulcerative colitis. Int J Colorectal Dis 1998; 13(2):61-67.
157. 157 Hugot JP, Touali H, Lesage S, Thomas G: Etiology of the inflammatory bowel diseases. Int J Colorectal Dis 1999; 14:2-9.
158. 158 Schreiber S, Hampe J: Genetics in GI disease: How much can we learn from the molecular analysis? Int J Colorectal Dis 1999; 14:10-12.
159. 159 Schreiber S: Morbus Crohn und Colitis ulcerosa - Aspekte zur Pathophysiologie. Leber Magen Darm 1997; 29 (S3):34-39.
160. 160 Stokkers PC, de Heer K, Leegwater AC, Reitsma PH, Tytgat GN, van Deventer SJ: Inflammatory bowel disease and the genes for the natural resistance-associated macrophage protein-1 and the interferon-gamma receptor 1. Int J Colorectal Dis 1999; 14(1):13-17.
161. 161 Kuhbacher T, Schreiber S, Runkel N: Pouchitis: pathophysiology and treatment. Int J Colorectal Dis 1998; 13(5-6):196-207.